Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine

Schizophrenia Research

Volumn 141, Issue 1, 2012, Pages 22-28

  Roiz Santiáñez, Roberto ^a,b   Tordesillas Gutiérrez, Diana ^a,b   Ortíz García de la Foz, Victor ^a,b   Ayesa Arriola, Rosa ^a,b   Gutiérrez, Agustín ^a   Tabarés Seisdedos, Rafael ^b,c   Vázquez Barquero, José Luis ^a,b   Crespo Facorro, Benedicto ^a,b  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Antipsychotic drugs; Brain; First episode psychosis; Neuroimaging; Schizophrenia

Indexed keywords

BIPERIDEN; CLONAZEPAM; HALOPERIDOL; LORMETAZEPAM; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTRALINE; ZIPRASIDONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COGNITION; CONTROLLED STUDY; CORTICAL THICKNESS; DRUG EFFECT; DRUG SUBSTITUTION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; FRONTAL LOBE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; LONGITUDINAL STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NERVOUS SYSTEM PARAMETERS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CEREBRAL CORTEX; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HALOPERIDOL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84865977527     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.07.014     Document Type: Article

References (48)

1. Agartz I., Okuguwa G., Nordstrom M., Greitz D., Magnotta V., Sedvall G. Reliability and reproducibility of brain tissue volumetry from segmented MR scans. Eur. Arch. Psychiatry Clin. Neurosci. 2001, 251(6):255-261.
2. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS) 1983, University of Iowa, Iowa City.
3. Andreasen N.C. The Scale for the Assessment of Positive Symptoms (SAPS) 1984, University of Iowa, Iowa City.
4. Andreasen N.C., Flaum M., Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch. Gen. Psychiatry 1992, 49(8):615-623.
5. Andreasen N.C., Rajarethinam R., Cizadlo T., Arndt S., Swayze V.W., Flashman L.A., O'Leary D.S., Ehrhardt J.C., Yuh W.T. Automatic atlas-based volume estimation of human brain regions from MR images. J. Comput. Assist. Tomogr. 1996, 20(1):98-106.
6. Cobia D.J., Csernansky J.G., Wang L. Cortical thickness in neuropsychologically near-normal schizophrenia. Schizophr. Res. 2011, 133(1-3):68-76.
7. Crespo-Facorro B., Perez-Iglesias R., Ramirez-Bonilla M., Martinez-Garcia O., Llorca J., Luis Vazquez-Barquero J. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J. Clin. Psychiatry 2006, 67(10):1511-1521.
8. Crespo-Facorro B., Roiz-Santianez R., Perez-Iglesias R., Pelayo-Teran J.M., Rodriguez-Sanchez J.M., Tordesillas-Gutierrez D., Ramirez M., Martinez O., Gutierrez A., de Lucas E.M., Vazquez-Barquero J.L. Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(8):1936-1943.
9. Crespo-Facorro B., Roiz-Santianez R., Perez-Iglesias R., Tordesillas-Gutierrez D., Mata I., Rodriguez-Sanchez J.M., de Lucas E.M., Vazquez-Barquero J.L. Specific brain structural abnormalities in first-episode schizophrenia. A comparative study with patients with schizophreniform disorder, non-schizophrenic non-affective psychoses and healthy volunteers. Schizophr. Res. 2009, 115(2-3):191-201.
10. Crespo-Facorro B., Roiz-Santianez R., Perez-Iglesias R., Rodriguez-Sanchez J.M., Mata I., Tordesillas-Gutierrez D., Sanchez E., Tabares-Seisdedos R., Andreasen N., Magnotta V., Vazquez-Barquero J.L. Global and regional cortical thinning in first-episode psychosis patients: relationships with clinical and cognitive features. Psychol. Med. 2011, 41(7):1449-1460.
11. Dazzan P., Morgan K.D., Orr K., Hutchinson G., Chitnis X., Suckling J., Fearon P., McGuire P.K., Mallett R.M., Jones P.B., Leff J., Murray R.M. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 2005, 30(4):765-774.
12. DeLisi L.E., Sakuma M., Maurizio A.M., Relja M., Hoff A.L. Cerebral ventricular change over the first 10 years after the onset of schizophrenia. Psychiatry Res. 2004, 130(1):57-70.
13. Dorph-Petersen K.A., Pierri J.N., Perel J.M., Sun Z., Sampson A.R., Lewis D.A. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005, 30(9):1649-1661.
14. Ehrlich S., Brauns S., Yendiki A., Ho B.C., Calhoun V., Schulz S.C., Gollub R.L., Sponheim S.R. Associations of cortical thickness and cognition in patients with schizophrenia and healthy controls. Schizophr Bull 2011, (Mar 24). 10.1093/schbul/sbr018.
15. First M.B., S.R., Gibbon M., Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders - Non Patient Edition 2001, New York State Psychiatric Institute, New York.
16. Garver D.L., Holcomb J.A., Christensen J.D. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol. Psychiatry 2005, 58(1):62-66.
17. Goldman A.L., Pezawas L., Mattay V.S., Fischl B., Verchinski B.A., Chen Q., Weinberger D.R., Meyer-Lindenberg A. Widespread reductions of cortical thickness in schizophrenia and spectrum disorders and evidence of heritability. Arch. Gen. Psychiatry 2009, 66(5):467-477.
18. Gonzalez-Blanch C., Crespo-Facorro B., Alvarez-Jimenez M., Rodriguez-Sanchez J.M., Pelayo-Teran J.M., Perez-Iglesias R., Vazquez-Barquero J.L. Cognitive dimensions in first-episode schizophrenia spectrum disorders. J. Psychiatr. Res. 2007, 41(11):968-977.
19. Gutierrez-Galve L., Wheeler-Kingshott C.A., Altmann D.R., Price G., Chu E.M., Leeson V.C., Lobo A., Barker G.J., Barnes T.R., Joyce E.M., Ron M.A. Changes in the frontotemporal cortex and cognitive correlates in first-episode psychosis. Biol. Psychiatry 2010, 68(1):51-60.
20. Harris G., Andreasen N.C., Cizadlo T., Bailey J.M., Bockholt H.J., Magnotta V.A., Arndt S. Improving tissue classification in MRI: a three-dimensional multispectral discriminant analysis method with automated training class selection. J. Comput. Assist. Tomogr. 1999, 23(1):144-154.
21. Ho B.C., Andreasen N.C., Ziebell S., Pierson R., Magnotta V. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 2011, 68(2):128-137.
22. Kuperberg G.R., Broome M.R., McGuire P.K., David A.S., Eddy M., Ozawa F., Goff D., West W.C., Williams S.C., van der Kouwe A.J., Salat D.H., Dale A.M., Fischl B. Regionally localized thinning of the cerebral cortex in schizophrenia. Arch. Gen. Psychiatry 2003, 60(9):878-888.
23. Lieberman J.A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry 1999, 46(6):729-739.
24. Lieberman J., Chakos M., Wu H., Alvir J., Hoffman E., Robinson D., Bilder R. Longitudinal study of brain morphology in first episode schizophrenia. Biol. Psychiatry 2001, 49(6):487-499.
25. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch. Gen. Psychiatry 2005, 62(4):361-370.
26. Magnotta V.A., Andreasen N.C., Schultz S.K., Harris G., Cizadlo T., Heckel D., Nopoulos P., Flaum M. Quantitative in vivo measurement of gyrification in the human brain: changes associated with aging. Cereb. Cortex 1999, 9(2):151-160.
27. Magnotta V.A., Harris G., Andreasen N.C., O'Leary D.S., Yuh W.T., Heckel D. Structural MR image processing using the BRAINS2 toolbox. Comput. Med. Imaging Graph. 2002, 26(4):251-264.
28. Mattai A., Chavez A., Greenstein D., Clasen L., Bakalar J., Stidd R., Rapoport J., Gogtay N. Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia. Schizophr. Res. 2010, 116(1):44-48.
29. Narr K.L., Bilder R.M., Toga A.W., Woods R.P., Rex D.E., Szeszko P.R., Robinson D., Sevy S., Gunduz-Bruce H., Wang Y.P., DeLuca H., Thompson P.M. Mapping cortical thickness and gray matter concentration in first episode schizophrenia. Cereb. Cortex 2005, 15(6):708-719.
30. Narr K.L., Toga A.W., Szeszko P., Thompson P.M., Woods R.P., Robinson D., Sevy S., Wang Y., Schrock K., Bilder R.M. Cortical thinning in cingulate and occipital cortices in first episode schizophrenia. Biol. Psychiatry 2005, 58(1):32-40.
31. Navari S., Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol. Med. 2009, 39(11):1763-1777.
32. Nesvag R., Lawyer G., Varnas K., Fjell A.M., Walhovd K.B., Frigessi A., Jonsson E.G., Agartz I. Regional thinning of the cerebral cortex in schizophrenia: effects of diagnosis, age and antipsychotic medication. Schizophr. Res. 2008, 98(1-3):16-28.
33. Okugawa G., Takase K., Nobuhara K., Yoshida T., Minami T., Tamagaki C., Magnotta V.A., Andreasen N.C., Kinoshita T. Inter- and intraoperator reliability of brain tissue measures using magnetic resonance imaging. Eur. Arch. Psychiatry Clin. Neurosci. 2003, 253(6):301-306.
34. Olabi B., Ellison-Wright I., McIntosh A.M., Wood S.J., Bullmore E., Lawrie S.M. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol. Psychiatry 2011, 70(1):88-96.
35. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971, 9(1):97-113.
36. Overall J.E., Gorman D.R. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962, 10:799-821.
37. Panizzon M.S., Fennema-Notestine C., Eyler L.T., Jernigan T.L., Prom-Wormley E., Neale M., Jacobson K., Lyons M.J., Grant M.D., Franz C.E., Xian H., Tsuang M., Fischl B., Seidman L., Dale A., Kremen W.S. Distinct genetic influences on cortical surface area and cortical thickness. Cereb. Cortex 2009, 19(11):2728-2735.
38. Pelayo-Teran J.M., Perez-Iglesias R., Ramirez-Bonilla M., Gonzalez-Blanch C., Martinez-Garcia O., Pardo-Garcia G., Rodriguez-Sanchez J.M., Roiz-Santianez R., Tordesillas-Gutierrez D., Mata I., Vazquez-Barquero J.L., Crespo-Facorro B. Epidemiological factors associated with treated incidence of first-episode non-affective psychosis in Cantabria: insights from the Clinical Programme on Early Phases of Psychosis. Early Interv. Psychiatry 2008, 2(3):178-187.
39. Roiz-Santianez R., Perez-Iglesias R., Quintero C., Tordesillas-Gutierrez D., Mata I., Ayesa R., Sanchez J.M., Gutierrez A., Sanchez E., Vazquez-Barquero J.L., Crespo-Facorro B. Insular cortex thinning in first episode schizophrenia patients. Psychiatry Res. 2010, 182(3):216-222.
40. Schultz C.C., Koch K., Wagner G., Roebel M., Schachtzabel C., Gaser C., Nenadic I., Reichenbach J.R., Sauer H., Schlosser R.G. Reduced cortical thickness in first episode schizophrenia. Schizophr. Res. 2010, 116(2-3):204-209.
41. van Haren N.E., Schnack H.G., Cahn W., van den Heuvel M.P., Lepage C., Collins L., Evans A.C., Hulshoff Pol H.E., Kahn R.S. Changes in cortical thickness during the course of illness in schizophrenia. Arch. Gen. Psychiatry 2011, 68(9):871-880.
42. Venkatasubramanian G., Jayakumar P.N., Gangadhar B.N., Keshavan M.S. Automated MRI parcellation study of regional volume and thickness of prefrontal cortex (PFC) in antipsychotic-naive schizophrenia. Acta Psychiatr. Scand. 2008, 117(6):420-431.
43. Vita A., De Peri L., Silenzi C., Dieci M. Brain morphology in first-episode schizophrenia: a meta-analysis of quantitative magnetic resonance imaging studies. Schizophr. Res. 2006, 82(1):75-88.
44. Weinberger D.R., McClure R.K. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain?. Arch. Gen. Psychiatry 2002, 59(6):553-558.
45. White T., Andreasen N.C., Nopoulos P., Magnotta V. Gyrification abnormalities in childhood- and adolescent-onset schizophrenia. Biol. Psychiatry 2003, 54(4):418-426.
46. Wiegand L.C., Warfield S.K., Levitt J.J., Hirayasu Y., Salisbury D.F., Heckers S., Dickey C.C., Kikinis R., Jolesz F.A., McCarley R.W., Shenton M.E. Prefrontal cortical thickness in first-episode psychosis: a magnetic resonance imaging study. Biol. Psychiatry 2004, 55(2):131-140.
47. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.
48. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 2000, 157(1):16-25.